Certain genes may increase your risk of developing MASH. Family history may play a role in your likelihood of developing the ...

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early ...

Metabolic-associated steatohepatitis (MASH) is an advanced and progressive liver disease that potentially causes cirrhosis ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Metabolic-associated steatohepatitis (MASH) is an advanced and progressive liver disease that potentially causes cirrhosis and hepatocellular ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

Oncoustics Oncoustics initiates FDA study of the OnX Liver Assessment Solution at clinical sites across the US and Canada marking a milesto ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH.

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting approximately 30% of the global population, ...